HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY DETERMINATION OF PRAVASTATIN IN PLASMA

被引:25
作者
IACONA, I [1 ]
REGAZZI, MB [1 ]
BUGGIA, I [1 ]
VILLANI, P [1 ]
FIORITO, V [1 ]
MOLINARO, M [1 ]
GUARNONE, E [1 ]
机构
[1] IRCCS,POLICLIN S MATTEO,DEPT PHARMACOL,P GOLGI 2,I-27100 PAVIA,ITALY
关键词
PRAVASTATIN; HYPERCHOLESTEROLEMIA; HEART TRANSPLANTATION; HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY; CYCLOSPORINE-A;
D O I
10.1097/00007691-199404000-00014
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Pravastatin is a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor that reduces plasma cholesterol levels. Some analytical methods have been described for determination of pravastatin levels in biological fluids, but these methods are rather cumbersome and involve expensive specialized equipment, usually not available in a clinical setting. A new technique, reversed-phase high-performance liquid chromatography (HPLC) with ultraviolet (UV) detection capability, has been developed for the analytical determination of pravastatin in plasma. Extraction and sample clean-up procedures are simple and rapid to execute, yet yield chromatograms virtually free of interference from endogenous plasma constituents and other antihypercholesterolemic agents or drugs usually taken concomitantly with pravastatin. Our detection limit for pravastatin was 2 ng/ml. Standard curves were linear between 5 and 200 ng/ml, with a coefficient of variation (CV) of < 10% at the limits of quantitation. This method was used to study pravastatin plasma levels in two hypercholesterolemic heart-transplant recipients and two hypercholesterolemic nontransplanted patients. We conclude that the method reported here would be ideal for therapeutic pravastatin monitoring in patients.
引用
收藏
页码:191 / 195
页数:5
相关论文
共 14 条
[1]  
Alberts A. W., 1990, DRUG INVEST S2, V2, P9
[2]   CURRENT THERAPY FOR HYPERCHOLESTEROLEMIA [J].
BLUM, CB ;
LEVY, RI .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1989, 261 (24) :3582-3587
[3]   LIPID LOWERING DRUGS [J].
BOCANEGRA, TS ;
TOBERT, JA .
BRITISH MEDICAL JOURNAL, 1990, 300 (6733) :1195-1195
[4]   RHABDOMYOLYSIS AND RENAL INJURY WITH LOVASTATIN USE - REPORT OF 2 CASES IN CARDIAC TRANSPLANT RECIPIENTS [J].
CORPIER, CL ;
JONES, PH ;
SUKI, WN ;
LEDERER, ED ;
QUINONES, MA ;
SCHMIDT, SW ;
YOUNG, JB .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1988, 260 (02) :239-241
[5]   DRUGS INHIBITING HMG-COA REDUCTASE [J].
ENDO, A .
PHARMACOLOGY & THERAPEUTICS, 1985, 31 (03) :257-267
[6]   CLINICAL IMPLICATIONS OF NEW DRUGS FOR LOWERING PLASMA-CHOLESTEROL CONCENTRATIONS [J].
ILLINGWORTH, DR .
DRUGS, 1991, 41 (02) :151-160
[7]  
JUNGNICKEL PW, 1992, CLIN PHARMACY, V11, P677
[8]   PRAVASTATIN - A REVIEW OF ITS PHARMACOLOGICAL PROPERTIES AND THERAPEUTIC POTENTIAL IN HYPERCHOLESTEROLEMIA [J].
MCTAVISH, D ;
SORKIN, EM .
DRUGS, 1991, 42 (01) :65-89
[9]  
NORMAN DJ, 1988, NEW ENGL J MED, V318, P46
[10]   COMPARATIVE PHARMACOKINETICS AND PHARMACODYNAMICS OF PRAVASTATIN AND LOVASTATIN [J].
PAN, HY ;
DEVAULT, AR ;
WANGIVERSON, D ;
IVASHKIV, E ;
SWANSON, BN ;
SUGERMAN, AA .
JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 30 (12) :1128-1135